MFHAS1 promotes colorectal cancer progress by regulating polarization of tumor-associated macrophages via STAT6 signaling pathway

Oncotarget

Volumn 7, Issue 48, 2016, Pages 78726-78735

  Chen, Wankun ^a   Xu, Yajun ^a   Zhong, Jing ^a   Wang, Huihui ^a   Weng, Meilin ^a   Cheng, Qian ^a   Wu, Qichao ^a   Sun, Zhirong ^a   Jiang, Hui ^a   Zhu, Minmin ^a   Ren, Yu ^a   Xu, Pingbo ^a   Chen, Jiawei ^a   Miao, Changhong ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Colorectal cancer; Macrophage polarization; MFHAS1; Tumor associated macrophages

Indexed keywords

KRUPPEL LIKE FACTOR 4; ONCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN MFHAS1; ROSIGLITAZONE; STAT6 PROTEIN; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL CYCLE PROTEIN; CELL SURFACE RECEPTOR; DNA BINDING PROTEIN; KRUPPEL LIKE FACTOR; LECTIN; MANNOSE BINDING LECTIN; MANNOSE RECEPTOR; MFHAS1 PROTEIN, HUMAN; STAT6 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POLARIZATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; ADENOCARCINOMA; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; CELL COMMUNICATION; COLORECTAL TUMOR; DISEASE EXACERBATION; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; MACROPHAGE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHENOTYPE; RAW 264.7 CELL LINE; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; CELL COMMUNICATION; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LECTINS, C-TYPE; MACROPHAGES; MALE; MANNOSE-BINDING LECTINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM STAGING; ONCOGENE PROTEINS; PHENOTYPE; PPAR GAMMA; RAW 264.7 CELLS; RECEPTORS, CELL SURFACE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84998854318     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12807     Document Type: Article

References (39)

1. Silva MT. Neutrophils and macrophages work in concert as inducers and effectors of adaptive immunity against extracellular and intracellular microbial pathogens. J Leukoc Biol. 2010; 87:805-13.
2. Xu JM, Shi GP. Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev. 2012; 33:71-108.
3. Chazaud B. Macrophages. supportive cells for tissue repair and regeneration. Immunobiology. 2014; 219:172-8.
4. Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015; 36:229-39.
5. McCabe A, MacNamara KC. Macrophages: Key regulators of steady-state and demand-adapted hematopoiesis. Exp Hematol. 2016; 44:213-22.
6. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005; 23:344-6.
7. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8:958-69.
8. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol. 2007; 37:14-6.
9. Hu W, Li X, Zhang C, Yang Y, Jiang J, Wu C. Tumorassociated macrophages in cancers. Clin Transl Oncol 2016; 18:251-8.
10. Chanmee T, Ontong P, Konno K, Itano N. Tumorassociated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014; 6:1670-90.
11. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4:71-8
12. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141:39-51.
13. Herwig MC, Bergstrom C, Wells JR, Holler T, Grossniklaus HE. M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles. Exp Eye Res. 2013; 107:52-8.
14. Sugimura K, Miyata H, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y. High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. J Surg Oncol. 2015; 111:752-9.
15. Hu H, Hang JJ, Han T, Zhuo M, Jiao F, Wang LW. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumour Biol. 2016; 37:8657-64.
16. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumorassociated macrophages: Potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev. 2016; 99:180-5.
17. Komohara Y, Niino D, Saito Y, Ohnishi K, Horlad H, Ohshima K, Takeya M. Clinical significance of CD163(+) tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci. 2013; 104:945-51.
18. Zhou X, Qi Y. Larynx carcinoma regulates tumor-associated macrophages through PLGF signaling. Sci Rep. 2015; 5:10071.
19. Sakabe T, Shinomiya T, Mori T, Ariyama Y, Fukuda Y, Fujiwara T, Nakamura Y, Inazawa J. Identification of a novel gene, MASL1, within an amplicon at 8p23.1 detected in malignant fibrous histiocytomas by comparative genomic hybridization. Cancer Res. 1999; 59:511-5.
20. Tagawa H, Karnan S, Kasugai Y, Tuzuki S, Suzuki R, Hosokawa Y, Seto M. MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8. Oncogene. 2004; 23:2576-81.
21. Dihanich S. MASL1: a neglected ROCO protein. Biochem Soc Trans. 2012; 40:1090-4.
22. Juhas U, Ryba-Stanislawowska M, Szargiej P, Mysliwska J. Different pathways of macrophage activation and polarization. Postepy Hig Med Dosw (Online). 2015; 69:496-502.
23. Liao X, Sharma N, Kapadia F, Zhou G, Lu Y, Hong H, Paruchuri K, Mahabeleshwar GH, Dalmas E, Venteclef N, Flask CA, Kim J, Doreian BW, et al. Kruppel-like factor 4 regulates macrophage polarization. J Clin Invest. 2011; 121:2736-49.
24. Wang Y, Moreland M, Wagner JG, Ames BN, Illek B, Peden DB, Jiang Q. Vitamin E forms inhibit IL-13/STAT6-induced eotaxin-3 secretion by up-regulation of PAR4, an endogenous inhibitor of atypical PKC in human lung epithelial cells. J Nutr Biochem. 2012; 23:602-8.
25. Meng F, Li C, Li W, Gao Z, Guo K, Song S: Interaction between pancreatic cancer cells and tumor-associated macrophages promotes the invasion of pancreatic cancer cells and the differentiation and migration of macrophages. IUBMB Life. 2014; 66:835-46.
26. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998; 273:25573-80.
27. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G. PPARgamma activation primes human monocytes into alternative M2 macrophages with antiinflammatory properties. Cell Metab 2007; 6:137-43.
28. Deng X, Zhang P, Liang T, Deng S, Chen X, Zhu L. Ovarian cancer stem cells induce the M2 polarization of macrophages through the PPARgamma and NF-kappaB pathways. Int J Mol Med. 2015; 36:449-54.
29. Ramakers JD, Verstege MI, Thuijls G, Te VA, Mensink RP, Plat J. The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J Clin Immunol. 2007; 27:275-83.
30. Chanmee T, Ontong P, Konno K, Itano N. Tumorassociated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014; 6:1670-90.
31. Takeya M, Komohara Y. Role of tumor-associated macrophages in human malignancies: friend or foe? Pathol Int. 2016; 66:491-505.
32. Hayashi N, Kataoka H, Yano S, Tanaka M, Moriwaki K, Akashi H, Suzuki S, Mori Y, Kubota E, Tanida S, Takahashi S, Joh T. A novel photodynamic therapy targeting cancer cells and tumor-associated macrophages. Mol Cancer Ther. 2015; 14:452-60.
33. Kimura Y, Sumiyoshi M. Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and/or G1 arrest in tumor cells. Eur J Pharmacol. 2015; 746:115-25.
34. Olsson A, Nakhle J, Sundstedt A, Plas P, Bauchet AL, Pierron V, Bruetschy L, Deronic A, Torngren M, Liberg D, Schmidlin F, Leanderson T. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. J Immunother Cancer. 2015; 3:53.
35. Kimura Y, Sumiyoshi M, Baba K. Antitumor and Antimetastatic Activity of Synthetic Hydroxystilbenes Through Inhibition of Lymphangiogenesis and M2 Macrophage Differentiation of Tumor-associated Macrophages. Anticancer Res. 2016; 36:137-48.
36. Ng AC, Eisenberg JM, Heath RJ, Huett A, Robinson CM, Nau GJ, Xavier RJ. Human leucine-rich repeat proteins: a genome-wide bioinformatic categorization and functional analysis in innate immunity. Proc Natl Acad Sci USA. 2011; 108:4631-8.
37. Zhong J, Shi QQ, Zhu MM, Shen J, Wang HH, Ma D, Miao CH. MFHAS1 Is Associated with Sepsis and Stimulates TLR2/NF-kappaB Signaling Pathway Following Negative Regulation. PLoS One. 2015; 10:e0143662.
38. Nemenoff R. Activation of PPARgamma in myeloid cells promotes lung cancer progression and metastasis. Oncoimmunology. 2012; 1:403-404.
39. Sawayama H, Ishimoto T, Watanabe M, Yoshida N, Sugihara H, Kurashige J, Hirashima K, Iwatsuki M, Baba Y, Oki E, Morita M, Shiose Y, Baba H. Small molecule agonists of PPAR-gamma exert therapeutic effects in esophageal cancer. Cancer Res. 2014; 74:575-85.